2026-04-17T19:09:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/124252025-12-24T08:52:47Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc López Muñoz, Laura author Pastor Maeso, Manuel author Sanz, Ferran author Selent, Jana author 2011-07-27T08:27:56Z 2011-07-27T08:27:56Z 2008 Schizophrenia is a devastating mental disorder that has a large/nimpact on the quality of life for those who are afflicted and is/nvery costly for families and society.[1] Although the etiology of/nschizophrenia is still unknown and no cure has yet been/nfound, it is treatable, and pharmacological therapy often produces/nsatisfactory results. Among the various antipsychotic/ndrugs in use, clozapine is widely recognized as one ofthe/nmost clinically effective agents, even if it elicits significant side/neffects such as metabolic disorders and agranulocytosis. Clozapine/nand the closely related compound olanzapine are good/nexamples ofdrug s with a complex multi-receptor profile ;[2]/nthey have affinities toward serotonin, dopamine, a adrenergic,/nmuscarinic, and histamine receptors, among others. Serotonina Esquizofrènia -- Quimioteràpia Esquizofrènia Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta (2) adrenergic receptor template